1 September 2024

Quarterly Cashflow Report - December 2010

Melbourne, Australia; Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) released  today the Quarterly Cash Flow Report (Appendix 4C) for the quarter ended 31 December 2010.

 

The cash balance at 31 December 2010 was $19.7m compared to $22.8m at 30 June 2010.

 

The Operating & Investing cash outflow of $1.5m for the quarter includes costs of the phase 2 bacterial vaginosis (BV) program.  Progress with the Phase 2 BV acute-treatment study for VivaGel®, which commenced in July 2010 has been pleasing, with 90% of patients (119 from a total of 132) now enrolled.

 

The December quarter result also includes financing cash flow proceeds of $1.2m from the exercise of share options.

 

Download ASX Announcement: Appendix 4C - December 2010 ( pdf file, 59kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.